US Stock MarketDetailed Quotes

BVS Bioventus

Watchlist
  • 11.420
  • +0.320+2.88%
Close Dec 10 16:00 ET
  • 11.420
  • 0.0000.00%
Post 17:14 ET
746.50MMarket Cap-18721P/E (TTM)

About Bioventus Company

Bioventus, Inc. is a medical technology company, which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. It operates through the following business segments: Active Healing Therapies-U.S, Active Healing Therapies-International, Surgical and BMP. The Active Healing Therapies-U.S and International offers two types of non-surgical products which are non-invasive exogen system for long bone stimulation for fracture healing and hyaluronic acid, or HA, viscosupplementation therapies for osteoarthritis pain relief. The Surgical segment offers a portfolio of advanced bone graft substitutes. The BMP segment comprises proprietary next-generation bone morphogenetic protein, or BMP. The company was founded on November 23, 2011 and is headquartered in Durham, NC.

Company Profile

SymbolBVS
Company NameBioventus
Listing DateFeb 11, 2021
Issue Price13.00
Founded2015
CEOMr. Robert E. Claypoole
MarketNASDAQ
Employees970
Fiscal Year Ends12-31
Address4721 Emperor Boulevard,Suite 100
CityDurham
ProvinceNorth Carolina
CountryUnited States of America
Zip Code27703
Phone1-919-474-6700

Company Executives

  • Name
  • Position
  • Salary
  • Robert E. Claypoole
  • Director, President and Chief Executive Officer
  • --
  • Mark Leonard Singleton
  • Senior Vice President, Chief Financial Officer and Principal Accounting Officer
  • 1.06M
  • Katrina Church
  • Senior Vice President and Chief Compliance Officer
  • --
  • Anthony D’Adamio
  • Senior Vice President and General Counsel
  • 924.52K
  • William A. Hawkins, III
  • Chairman of the Board
  • 199.48K
  • Philip G. Cowdy
  • Independent Director
  • --
  • John A. Bartholdson
  • Independent Director
  • 211.70K
  • Michelle McMurry-Heath
  • Independent Director
  • 156.98K
  • Guy P. Nohra
  • Independent Director
  • 153.23K
  • Patrick J. Beyer
  • Independent Director
  • 150.73K
  • Guido J. Neels
  • Independent Director
  • 148.23K
  • Susan M. Stalnecker
  • Independent Director
  • 165.73K
  • Mary Katherine Ladone
  • Independent Director
  • 158.23K
  • Martin P. Sutter
  • Independent Director
  • 150.73K
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.